SFM
IOVA icon

Systematic Financial Management’s Iovance Biotherapeutics IOVA Stock Holding History

Systematic Financial Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,809
Closed -$47.7K – 271
2023
Q1 		$47.7K Buy
+7,809
New +$53.9K ﹤0.01% 289

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Systematic Financial Management's IOVA Position: Q2 2023 in Review

Systematic Financial Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 7,809 shares — an estimated $47.7K sold.

Systematic Financial Management first reported a position in IOVA in Q1 2023 and held it in 1 quarter. The position peaked at $47.7K in Q1 2023. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Systematic Financial Management reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Systematic Financial Management sold 7,809 Iovance Biotherapeutics shares in Q2 2023, an estimated $47.7K.
  • Systematic Financial Management first reported a position in Iovance Biotherapeutics in Q1 2023 and held it in 1 quarter.
  • Systematic Financial Management's Iovance Biotherapeutics position peaked at $47.7K in Q1 2023.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Systematic Financial Management's 13F filing for Q2 2023, filed 14 Aug 2023.